UNSPSC 51313118: Homochlorcyclizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M1YE3TK8NA, chemically known as (+/-)-homochlorcyclizine dihydrochloride, but more generally known as homochlorcyclizine dihydrochloride, which bears US NIH Compound Identifier 16114. European Medicines Agency schedules homochlorcyclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG.

Most nations, for tariff purposes, schedule homochlorcyclizine dihydrochloride under HS 29339940. SMILES: CN1CCCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.

UNSPSC 51313118 Homochlorcyclizine dihydrochloride is a Commodity code that in recent state and local procurement activity does not align with its nominal pharmaceutical-chemical scope. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which concern homochlorcyclizine dihydrochloride specifically. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). This suggests the code may be used as a catch-all for pharmaceutical procurement rather than tracking the specific active pharmaceutical ingredient.

Recent activity shows geographic concentration in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission posted a Request for Information (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer prescription models outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with contract effectiveness set for July 1, 2026. The mismatch between the code's nominal chemical description and the actual scope of recent solicitations signals that this code sees minimal relevant activity or is misapplied by issuing bodies tagging broader pharmaceutical procurement.